News Releases

Enrollment Completed in CAHptain-205 Study in Pediatric Classic Congenital Adrenal Hyperplasia (CAH) Target Enrollment Completed in CAHmelia-203 Study in Adult Classic CAH CAHmelia-204 Study in Adult Classic CAH on Track to Complete Enrollment in Early Q1 2024 SOUTH SAN FRANCISCO, Calif.

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 2, 2023-- Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company

Final Enrollment in CAHmelia-203 to Exceed Target Due to Substantial Patient Interest CAHmelia-203 Topline Results Anticipated in the First Quarter of 2024 CAHmelia-204 Completion of Enrollment Anticipated in Early First Quarter of 2024 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct.

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 28, 2023-- Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier

Spruce Reports Interim Data from Phase 2 POWER Proof-of-Concept Study in Polycystic Ovary Syndrome (PCOS) CAHmelia Program in Adult Classic Congenital Adrenal Hyperplasia (CAH) Surpasses 75% Enrollment in CAHmelia-203 and Approaches 75% Enrollment in CAHmelia-204 Screening Underway for Cohort 3 in

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 12, 2023-- Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a

Accomplished life sciences industry executive brings more than 20 years of commercial and biopharmaceutical expertise to Spruce Board SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 25, 2023-- Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 24, 2023-- Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier

Javier Szwarcberg , M.D., M.P.H., Chief Executive Officer, accepted the Corporate Partner Award SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 22, 2023-- Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies

CAHmelia Program in Adult Classic Congenital Adrenal Hyperplasia (CAH) Achieves 50% Enrollment in CAHmelia-204 and Approaches 75% Enrollment in CAHmelia-203 Enrollment in P.O.W.E.R. Study for Polycystic Ovary Syndrome (PCOS) Complete – Topline Results Anticipated in Q3 2023 Cohort 1 for Phase 2